DAVID S WILKES, MD
Osteopathic Medicine at University Blvd, Indianapolis, IN
License number
Indiana 01040120A
Category
Osteopathic Medicine
Type
Critical Care Medicine
License number
Indiana 01040120
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
550 N University Blvd, Indianapolis, IN 46202
Phone
(317) 278-4265
Personal information
See more information about DAVID S WILKES at radaris.comName
Address
Phone
5430 Sterling Dr APT 14, Granger, IN 46530
3380 Peppermill Dr APT 2B, W Lafayette, IN 47906
8023 Mill Pond Ln, Indianapolis, IN 46278
Professional information
See more information about DAVID S WILKES at trustoria.com
Dr. David S Wilkes, Indianapolis IN - MD (Doctor of Medicine)
Dr. David S Wilkes, Indianapolis IN - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
635 Barnhill Dr, Indianapolis 46202
(317) 274-3960 (Phone)
INDIANA UNIVERSITY SCHOOL OF MEDICINE
340 W 10Th St SUITE 6200, Indianapolis 46202
(317) 274-8157 (Phone), (317) 274-8439 (Fax)
(317) 274-3960 (Phone)
INDIANA UNIVERSITY SCHOOL OF MEDICINE
340 W 10Th St SUITE 6200, Indianapolis 46202
(317) 274-8157 (Phone), (317) 274-8439 (Fax)
Certifications:
Critical Care Medicine, 2001, Internal Medicine, 1985, Pulmonary Disease, 1992
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Temple University
Graduated: 1982
Temple University Hospital
Temple University
Graduated: 1982
Temple University Hospital
Restaurant Professional
Restaurant Professional
Location:
Indianapolis, Indiana Area
Industry:
Restaurants
Work:
Don Pablo's
1988 - 1999
-
Manager
Education:
University of Oklahoma 1981 - 1986
BBA, Finance
BBA, Finance
David Stephen Wilkes, Indianapolis IN
David Stephen Wilkes, Indianapolis IN
Specialties:
Internal Medicine, Critical Care Medicine, Pulmonary Disease, Emergency Medicine, Critical Care Medicine, Critical Care Medicine
Work:
Indiana University
550 University Blvd, Indianapolis, IN 46202 Indiana University Medical Group
200 W 103Rd St, Indianapolis, IN 46290 Indianapolis VA / Roudebush VAMC
1481 W 10Th St, Indianapolis, IN 46202 David C Wilks
8777 Broadway, Merrillville, IN 46410 Indiana Diabetes Center
1001 W 10Th St, Indianapolis, IN 46202
550 University Blvd, Indianapolis, IN 46202 Indiana University Medical Group
200 W 103Rd St, Indianapolis, IN 46290 Indianapolis VA / Roudebush VAMC
1481 W 10Th St, Indianapolis, IN 46202 David C Wilks
8777 Broadway, Merrillville, IN 46410 Indiana Diabetes Center
1001 W 10Th St, Indianapolis, IN 46202
Education:
Temple University Physicians (1982)
Method To Identify Patients At Risk For Lung Transplant Rejection
Method To Identify Patients At Risk For Lung Transplant Rejection
US Patent:
7939281, May 10, 2011
Filed:
Jun 25, 2010
Appl. No.:
12/823570
Inventors:
David S. Wilkes - Indianapolis IN, US
Michael J. Klemsz - Indianapolis IN, US
Michael J. Klemsz - Indianapolis IN, US
Assignee:
Indiana University Research and Technology Corporation - Indianapolis IN
International Classification:
G01N 33/543, A61K 39/00
US Classification:
435 721, 435 71, 436501, 424 91, 4241841, 530300, 530350, 530356
Abstract:
Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen.
Molecules For The Treatment Of Lung Disease Involving An Immune Reaction To Connective Tissue Found In The Lung
Molecules For The Treatment Of Lung Disease Involving An Immune Reaction To Connective Tissue Found In The Lung
US Patent:
7759075, Jul 20, 2010
Filed:
Jul 11, 2008
Appl. No.:
12/171661
Inventors:
David S. Wilkes - Indianapolis IN, US
Michael Klemsz - Indianapolis IN, US
Michael Klemsz - Indianapolis IN, US
Assignee:
Indiana University Research and Technology Corporation - Indianapolis IN
International Classification:
G01N 33/543, A61K 39/00
US Classification:
435 721, 435 71, 436501, 424 91, 4241841, 530300, 530350, 530356
Abstract:
Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen.
Oral Tolerance Induction By Collagen To Prevent Allograft Rejection
Oral Tolerance Induction By Collagen To Prevent Allograft Rejection
US Patent:
7348005, Mar 25, 2008
Filed:
Sep 13, 2002
Appl. No.:
10/243797
Inventors:
David S. Wilkes - Indianapolis IN, US
Assignee:
Advanced Research and Technology Institute - Indianapolis IN
International Classification:
A61K 39/00, A61K 39/38
US Classification:
4241841, 530356
Abstract:
The present invention relates to the use of collagen and MHC-like compounds to down regulate immune responses. Methods for administration of such compounds that induce immune tolerance are described. The invention is important in the context of allograft rejection, transplantation, graft rejection, pleural disease and immunotolerance.
Compositions For Use In The Treatment Of Chronic Obstructive Pulmonary Diseases And Asthma
Compositions For Use In The Treatment Of Chronic Obstructive Pulmonary Diseases And Asthma
US Patent:
2013019, Aug 1, 2013
Filed:
Mar 12, 2013
Appl. No.:
13/797556
Inventors:
Indiana University Research & Technology Corporation - Indianapolis IN, US
David S. Wilkes - Indianapolis IN, US
David S. Wilkes - Indianapolis IN, US
Assignee:
Indiana University Research & Technology Corporation - Indianapolis IN
International Classification:
A61K 39/00, G01N 33/68
US Classification:
4241851, 530356, 436501
Abstract:
The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.
Compositions For Use In The Treatment Of Chronic Obstructive Pulmonary Diseases And Asthma
Compositions For Use In The Treatment Of Chronic Obstructive Pulmonary Diseases And Asthma
US Patent:
8568730, Oct 29, 2013
Filed:
Apr 22, 2010
Appl. No.:
13/265847
Inventors:
David S. Wilkes - Indianapolis IN, US
Assignee:
Indiana University Research & Technology Corporation - Indianapolis IN
International Classification:
A61K 39/00
US Classification:
4241841, 514 122, 514 212, 514 172
Abstract:
The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.
Compounds And Methods For Inhibiting Mmp2 And Mmp9
Compounds And Methods For Inhibiting Mmp2 And Mmp9
US Patent:
2011029, Dec 1, 2011
Filed:
Feb 9, 2010
Appl. No.:
13/201413
Inventors:
David S. Wilkes - Indianapolis IN, US
International Classification:
A61K 31/38, A61P 37/06, A61K 31/336
US Classification:
4241841
Abstract:
The present invention relates to specific inhibitors of MMP2 and MMP9 and their use in immunosuppression.
